Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00440518 · ClinicalTrials.gov registry record · Phase 2

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

A Phase 2 study, sponsored by UCB Pharma.

Completed
Registry status
Phase 2
Development phase
218
Enrollment target

NCT00440518: Completed Phase 2 study, sponsored by UCB Pharma.

NCT00440518 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00440518, a Phase 2 study, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 2
Development phase
218 participants
Enrollment target

Study Summary

The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.

Interventions

  • OTHER Placebo
  • DRUG Lacosamide

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2007-02
Est. Completion 2008-07
Phase Phase 2
UCB Pharma

100 total trials

What the finished NCT00440518 record still lists

NCT00440518 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00440518 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00440518 about?

NCT00440518 is a clinical study titled "A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis". The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.

What is the current status of trial NCT00440518?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2007-02. Estimated completion is 2008-07.

What interventions are being tested in trial NCT00440518?

The interventions under investigation include: Placebo (OTHER), Lacosamide (DRUG).

Who is sponsoring clinical trial NCT00440518?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00440518's enrollment target sits among peer trials

218 284th of 2000 higher than 1,715 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04693858 · 218 participants · NA

    Efficacy Trial of the CALM Intervention

  • NCT05909202 · 218 participants · NA

    A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

  • NCT06000761 · 218 participants · NA

    Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

  • NCT06249126 · 218 participants · NA

    Primary Subtalar Arthrodesis for Calcaneal Fractures

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00440518, the US trial registry maintained by the National Library of Medicine. NCT00440518 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.